Oh and my initial comment was prior to conducting much research. Digging deeper into the clinical data I found evidence supportive of 2RT. However, it seems as if the market has only glanced at the data initially as I did myself and has completely written off the 2RT asset. If that is true (and it is an opinion held by one of the top 20 (non insider) holders as well) there is zero risk to reward (i.e. 2RT valuation is currently at rock bottom so can only go up) investing in the 2RT potential.
I will stop spamming this forum and get back to work!
Oh and my initial comment was prior to conducting much research....
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 19.0¢ | $22.41K | 115.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 109923 | 3 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |